Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer

Journal of Supportive Oncology

Volumn 7, Issue 6, 2009, Pages 225-228

  Schuman, Samer I ^a   Lambrou, Nicholas ^a   Robson, Katie ^a   Glück, Stefan ^a   Myriounis, Nikolaos ^a   Pearson, J Matt ^a   Lucci III, Joseph A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; PLATINUM COMPLEX; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GERM CELL TUMOR; HOSPITALIZATION; HUMAN; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OVARIAN GERM CELL TUMOR; OVARY CANCER; OVARY TUMOR; PERITONEUM CANCER; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENDOMETRIAL STROMAL TUMORS; FEMALE; FILGRASTIM; HUMANS; LEUKOCYTE COUNT; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; NEUTROPENIA; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73449139087     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Johnston E, Crawford J, blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522-2528. [10893282]
2. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or III/IV breast cancer. J Clin Oncol 2002;20:727-731. [11821454]
3. Green M. A single fixed dose of pegfilgrastim given once per chemotherapy cycle is as effective as daily filgrastim in the management of neutropenia in high-risk breast cancer. Eur J Cancer 2001;37(suppl 6):540.
4. Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of peg-filgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003;21:514-519. [12560443]
5. Watt Ly, Levin R, Musick RE. Same day dosing of pegfilgrastim in patients receiving fractionated dose chemotherapy. Pharmacotherapy 2003;23:105.
6. Baribeault DM. A single-center, observational study of neutropenic event rates for patients receiving chemotherapy and pegfilgrastim on the same day. American College of Clinical Pharmacology 2003. Abstract 4884.
7. Lokich J. Same-day pegfilgrastim and chemo-therapy. Cancer Invest 2005;23:573-576.[16305982]
8. Belani CP, Ramalingam S, Al-Janadi A, et al. A randomized double-blind phase II study to evaluate same-day vs next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC. J Clin Oncol 2006;24(18S):7110.
9. Whitworth JM, Matthews KS, Shipman KA, et al. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 2009;112:601-604. [19110303]
10. Kaufman PA, Paroly W, Rinaldi D, et al. Randomized, double-blind, phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with early stage and advanced breast cancer. breast Cancer Res Treat 2004. Abstract 1054.
11. Saven A, Schwartzberg L, Kaywin P, et al. Randomized, double-blind, phase 2 study evaluating same-day vs next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin's lymphoma patients. J Clin Oncol 2006;24(18S):7570.
12. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-3205. [16682719]
13. Green MD, Koelbl H, baselga J, et al. A ran-domized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35. [12488289]
14. Lokich JJ. Same day pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma. Am J Clin Oncol 2006;29:361-363.[16891862]
15. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:1682-1691.[15547181]
16. Bolis G, Scarfone G, Polverino G, et al. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial. J Clin Oncol 2004;22:686-690.[14966092]
17. Markman M, bundy bN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carbo-platin followed by intravenous paclitaxel and intra-peritoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-1007.[11181662]
18. Verschraegen CF, Sittisomwong T, Kudelka AP, et al. Docetaxel for patients with paclitaxel-resistant mullerian carcinoma. J Clin Oncol 2000;18:2733-2739. [10894873]
19. Bookman MA, Malmström H, bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16:3345-3352.[9779711]
20. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-977. [2348230]